160 related articles for article (PubMed ID: 35526235)
21. Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients.
McEneny-King A; Chelle P; Goggans MH; Barker PJ; Jacobs TW; Neufeld EJ; Reiss UM; Panetta JC
Haemophilia; 2021 May; 27(3):408-416. PubMed ID: 33742733
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.
Morfini M; Marchesini E; Paladino E; Santoro C; Zanon E; Iorio A
Haemophilia; 2015 Mar; 21(2):204-209. PubMed ID: 25274155
[TBL] [Abstract][Full Text] [Related]
23. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).
Goedhart TMHJ; Bukkems LH; Coppens M; Fijnvandraat KJ; Schols SEM; Schutgens REG; Eikenboom J; Heubel-Moenen FCJI; Ypma PF; Nieuwenhuizen L; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH
TH Open; 2022 Jan; 6(1):e60-e69. PubMed ID: 35280975
[TBL] [Abstract][Full Text] [Related]
24. Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors.
Lunghi B; Morfini M; Martinelli N; Branchini A; Linari S; Castaman G; Bernardi F
Haemophilia; 2023 Mar; 29(2):479-487. PubMed ID: 36533781
[TBL] [Abstract][Full Text] [Related]
25. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
26. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
[TBL] [Abstract][Full Text] [Related]
27. Impact of being overweight on factor VIII dosing in children with haemophilia A.
Henrard S; Hermans C
Haemophilia; 2016 May; 22(3):361-7. PubMed ID: 26558443
[TBL] [Abstract][Full Text] [Related]
28. Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
Astermark J; Olsson A; Chelle P; Täckström K; Walger M; Magnusson M; Iorio A
Haemophilia; 2021 Jul; 27(4):626-633. PubMed ID: 33966319
[TBL] [Abstract][Full Text] [Related]
29. Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A.
Singkham N; Punyawudho B; Yu MS; Cheng SN; Chen SH; Chang H; Chen CC; Hsiao CC; Hou JY; Fang YP; Wang HW; Lin JH; Yu LH; Chen YC
Haemophilia; 2022 Mar; 28(2):230-238. PubMed ID: 35060242
[TBL] [Abstract][Full Text] [Related]
30. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
31. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
32. Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target.
Schütte LM; de Rooij N; Hazendonk HCAM; Mathôt RAA; van Hest RM; Leebeek FWG; Cnossen MH; Kruip MJHA
Haemophilia; 2019 Nov; 25(6):960-968. PubMed ID: 31487098
[TBL] [Abstract][Full Text] [Related]
33. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.
Lunghi B; Bernardi F; Martinelli N; Frusconi S; Branchini A; Linari S; Marchetti G; Castaman G; Morfini M
J Thromb Haemost; 2019 Aug; 17(8):1288-1296. PubMed ID: 31055871
[TBL] [Abstract][Full Text] [Related]
34. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.
Xi Y; Jin C; Liu W; Zhou H; Wang Z; Zhou R; Lou S; Zhao X; Chen F; Cheng P; Sun Z; Jia H; Zhang L
Haemophilia; 2022 Nov; 28(6):e219-e227. PubMed ID: 35996199
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
Björkman S
Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
[TBL] [Abstract][Full Text] [Related]
37. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.
Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Monte E; Pérez-Alenda S; Bosch P; Querol F; Poveda JL
Thromb Res; 2019 Feb; 174():151-162. PubMed ID: 30634166
[TBL] [Abstract][Full Text] [Related]
38. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.
Kepa S; Horvath B; Reitter-Pfoertner S; Schemper M; Quehenberger P; Grundbichler M; Heistinger M; Neumeister P; Mannhalter C; Pabinger I
Haemophilia; 2015 May; 21(3):343-350. PubMed ID: 25582282
[TBL] [Abstract][Full Text] [Related]
39. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
[TBL] [Abstract][Full Text] [Related]
40. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]